Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer

被引:0
|
作者
Yang, Shi-Ping [1 ]
Liu, Ke [2 ]
Li, Yang [3 ]
Li, Guan-Qiao [4 ]
Li, Jia-Yi [5 ]
Lin, Yu-Yi [6 ,8 ]
Wu, San-Gang [7 ]
机构
[1] Hainan Med Univ, Hainan Gen Hosp, Dept Radiat Oncol, Hainan Affiliated Hosp, Haikou, Peoples R China
[2] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Tradit Chinese Med, Xiamen, Peoples R China
[3] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Peoples R China
[4] Hainan Med Univ, Hainan Gen Hosp, Dept Breast Surg, Hainan Affiliated Hosp, Haikou, Peoples R China
[5] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Sch Med, Xiamen, Peoples R China
[6] Xiamen Med Coll, Dept Radiat Oncol, Affiliated Hosp 2, Xiamen, Peoples R China
[7] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Sch Med, Xiamen, Peoples R China
[8] Xiamen Med Coll, Dept Radiat Oncol, Affiliated Hosp 2, Xiamen 361021, Peoples R China
关键词
Breast cancer; metastatic stage; Oncotype; prognosis; chemotherapy; POSITIVE NODES; PALBOCICLIB; LETROZOLE; THERAPY; IMPACT; ASSAY;
D O I
10.1080/14737159.2024.2301940
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Limited data exist regarding the utility and validity of the 21-gene recurrence score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to investigate the practice patterns as well as associated survival outcomes based on 21-gene RS in dnMBC.Research design and methods: The Surveillance, Epidemiology, and End Results Oncotype database was queried for women with hormone receptor-positive and Her2-negative dnMBC.Results: A total of 153 patients were identified, including 62.7% and 37.3% of patients who had RS < 26 and >= 26, respectively. Patients with RS >= 26 were more likely to receive chemotherapy compared to those with RS < 26 (61.4% vs. 28.1%, p < 0.001). Patients with RS >= 26 had an inferior breast cancer-specific survival (BCSS) (2-year BCSS: 84.3% vs. 89.5, p = 0.067) and overall survival (OS) compared to those with RS < 26 (2-year OS: 76.9% vs. 87.4%, p = 0.018). The multivariate Cox proportional hazard models showed that those with RS >= 26 had a significantly inferior BCSS (hazard ratio [HR] 2.251, 95% confidence interval [CI] 1.056-4.799, p = 0.036) and OS (HR 2.151, 95%CI 1.123-4.120, p = 0.021) compared to those with RS < 26.Conclusions: The 21-gene RS assay is an important prognostic factor in patients with dnMBC.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 50 条
  • [1] The 21-Gene Recurrence Score in Male Breast Cancer
    Gulisa Turashvili
    Monica Gonzalez-Loperena
    Edi Brogi
    Maura Dickler
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    [J]. Annals of Surgical Oncology, 2018, 25 : 1530 - 1535
  • [2] The 21-Gene Recurrence Score in Male Breast Cancer
    Turashvili, Gulisa
    Gonzalez-Loperena, Monica
    Brogi, Edi
    Dickler, Maura
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (06) : 1530 - 1535
  • [3] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Jegadeesh, Naresh K.
    Kim, Sunjin
    Prabhu, Roshan S.
    Oprea, Gabriela M.
    Yu, David S.
    Godette, Karen G.
    Zelnak, Amelia B.
    Mister, Donna
    Switchenko, Jeffrey M.
    Torres, Mylin A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1088 - 1094
  • [4] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Naresh K. Jegadeesh
    Sunjin Kim
    Roshan S. Prabhu
    Gabriela M. Oprea
    David S. Yu
    Karen G. Godette
    Amelia B. Zelnak
    Donna Mister
    Jeffrey M. Switchenko
    Mylin A. Torres
    [J]. Annals of Surgical Oncology, 2015, 22 : 1088 - 1094
  • [5] The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment
    Ethier, Josee-Lyne
    Amir, Eitan
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (04) : 307 - 313
  • [6] The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment
    Josee-Lyne Ethier
    Eitan Amir
    [J]. Molecular Diagnosis & Therapy, 2016, 20 : 307 - 313
  • [7] Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer
    Montemurro, Filippo
    Marchio, Caterina
    Sapino, Anna
    [J]. JAMA ONCOLOGY, 2020, 6 (04) : 584 - +
  • [8] Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer Reply
    Sparano, Joseph A.
    [J]. JAMA ONCOLOGY, 2020, 6 (04) : 586 - 586
  • [9] BREAST CANCER The 21-gene recurrence score - biology remains at the forefront
    Puhalla, Shannon L.
    Davidson, Nancy E.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 470 - 472
  • [10] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    [J]. CANCER RESEARCH, 2017, 77